Market Overview

UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic Inflection

Related CPHD
Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid
Benzinga's Top Downgrades

UBS Investment Research raises its rating on Cepheid (NASDAQ: CPHD) from Neutral to Buy and lifts its price target from $44 to $45.

UBS Investment Research says, "We are upgrading CPHD to Buy from Neutral, as a ~16% decline in shares since 3/26 (vs. ~5% for the S&P) has yielded an attractive buying opportunity, in our view. Overall business momentum appears solid, new product launches represent catalysts in 2H, and we view the company's profile (no exposure to NIH budgeting, relatively low sensitivity to EU macro issues) as favorable. While shares remain at a premium (EV/ '12 sales of 6.8x vs. 3.8x for CPHD's diagnostics peers), we believe valuation is backed by a robust growth forecast & M&A potential."

CPHD closed at $37.24 on Monday.

Latest Ratings for CPHD

Sep 2016BairdDowngradesOutperformNeutral
Sep 2016CitigroupDowngradesBuyNeutral
Sep 2016BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: UBS Investment ResearchAnalyst Color Upgrades Price Target Intraday Update Analyst Ratings


Related Articles (CPHD)

View Comments and Join the Discussion!